SCHEMBL14320889

SCHEMBL14320889

COC(=O)c1cccc(-c2nc(Nc3ccc4c(c3)NC(=O)CO4)c3[nH]ncc3n2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 9/20 0.46
PDE5A O76074 1/20 0.45
JAK1 P23458 1/20 0.43
JAK3 P52333 1/20 0.43
MAPT P10636 5/20 0.43
ABCG2 Q9UNQ0 2/20 0.43
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 4/20 0.43
POLB P06746 1/20 0.43
JAK2 O60674 1/20 0.42
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
MAPK1 P28482 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
GAA P10253 1/20 0.41
HTT P42858 1/20 0.41
ROCK2 O75116 1/20 0.41
ABCB1 P08183 1/20 0.41
HPGD P15428 1/20 0.40
CYP2C9 P11712 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14320598 0.92 SYK (0.47) SYKJAK1JAK3MAPTALDH1A1
SCHEMBL14320935 0.87 SYK (0.47) SYKJAK1JAK3MAPTALDH1A1
SCHEMBL14320820 0.86 CRBN (0.48) SYKPDE5AMAPTABCG2KDM4E
SCHEMBL14320447 0.86 SYK (0.55) SYKJAK1JAK3MAPTABCG2
SCHEMBL15651330 0.85 PDE5A (0.48) SYKPDE5AMAPTABCG2KDM4E
SCHEMBL14320404 0.85 LMNA (0.52) SYKPDE5AMAPTABCG2KDM4E
SCHEMBL14320602 0.85 MAPT (0.54) SYKJAK1JAK3MAPTABCG2
SCHEMBL14320504 0.85 PDE5A (0.44) SYKPDE5AMAPTABCG2KDM4E
SCHEMBL14321230 0.84 SYK (0.59) SYKMAPTABCG2KDM4EALDH1A1
SCHEMBL14320594 0.83 SYK (0.45) SYKJAK1JAK3MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US claimed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP claimed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US claimed
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US disclosed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP disclosed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329780-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK SYK 11/4885PDE5A 1895/4885JAK1 100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.